Lawrence Gensler, MD
Gastroenterology · Covington, LANPI 1841295953
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by AbbVie at 52.3% of the total. Reporting peaked in 2019 at $8,973 and has fallen 78.3% since, to $1,946 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 781 payments — averaging $39.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Phathom Pharmaceuticals, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- Sanofi$1K
- plus $5K from 28 others
What the payments were for
- Consulting fees$1,5605%
- Speaking & faculty fees$15,95551%
- Travel & lodging$2481%
- Food & beverage$13,21242%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 295 | $16,253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $5,817 |
| Phathom Pharmaceuticals, Inc. | 14 | $1,242 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 73 | $1,088 |
| Johnson & Johnson | 61 | $1,034 |
| Sanofi | 37 | $1,002 |
| Ironwood Pharmaceuticals, Inc | 71 | $829 |
| Bristol Myers Squibb | 28 | $445 |
| Janssen Scientific Affairs, LLC | 4 | $426 |
| Intercept Pharmaceuticals, Inc. | 16 | $397 |
| Pfizer | 21 | $325 |
| E.r. Squibb & Sons, L.L.C. | 3 | $306 |
| Merck | 20 | $284 |
| QOL Medical, LLC | 16 | $267 |
| Lilly USA, LLC | 8 | $205 |
| Ardelyx, Inc. | 8 | $157 |
| Regeneron Healthcare Solutions, Inc. | 7 | $157 |
| Boston Scientific | 7 | $134 |
| Novo Nordisk | 2 | $132 |
| Ipsen Biopharmaceuticals, Inc | 1 | $115 |
| Ferring Pharmaceuticals Inc. | 7 | $107 |
| Celltrion USA Inc. | 5 | $105 |
| Gilead | 4 | $67 |
| Evoke Pharma, Inc. | 2 | $27 |
| Organon | 2 | $27 |
| Amgen | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Shionogi Inc | 1 | $18 |
| UCB, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
| Mauna Kea Technologies, Inc. | 1 | $16 |
| Intra-sana Laboratories | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,105 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 158 | $152,481 |
| CreonLipase/Protease/Amylase | 14 | $65,982 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 59 | $9,915 |
| Mesalamine ErMesalamine | 52 | $8,395 |
| Pantoprazole Sodium | 719 | $7,850 |
| Rabeprazole Sodium | 157 | $7,475 |
| TrulancePlecanatide | 13 | $6,830 |
| Mesalamine | 25 | $6,376 |
| AprisoMesalamine | 13 | $6,212 |
| MotegrityPrucalopride Succinate | 12 | $6,162 |
| Sucralfate | 126 | $5,233 |
| Lubiprostone | 25 | $2,642 |
| Famotidine | 158 | $2,530 |
| Balsalazide Disodium | 22 | $1,676 |
| Lansoprazole | 37 | $911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $16,253 | $218,463172 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Apriso | $1,088 | $13,04126 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $107 | $9,91559 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $5,817 | $6,16212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Covington
- Nathaniel RanneyCovington$392K
- Lemuel JenkinsCovington$99K
- Felix RabitoCovington$41K
- Brandon BrousseCovington$16K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.